Get started
Author

Leonard M. Klein

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 587
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
2019 · Maria-Victoria Mateos, Hilary Blacklock, et al. · The Lancet Haematology · 258
PDF
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
2015 · Jeff Sharman, Michael Hawkins, et al. · Blood · 188
PDF
Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
2010 · Robert Jotte, Paul Conkling, et al. · Journal of Clinical Oncology · 176
Iatrogenic superior vena cava syndrome. A new entity
1984 · Marcelle Bertrand, Cary A. Presant, et al. · Cancer · 78
Abstract PD13-07: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer
2021 · Véronique Diéras, Robert Weaver, et al. · Cancer Research · 63
Ublituximab ( TG ‐1101), a novel glycoengineered anti‐ CD 20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
2016 · Jeff P. Sharman, Charles M. Farber, et al. · British Journal of Haematology · 63
PDF
Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide
2010 · I N M Micallef, A D Ho, et al. · Bone Marrow Transplantation · 62
Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
1996 · J D Bitran, B Samuels, et al. · PubMed · 62
An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
2018 · David J. Andorsky, Kathryn S. Kolibaba, et al. · British Journal of Haematology · 47
PDF
Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
1996 · J D Bitran, B Samuels, et al. · PubMed · 47
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-hodgkin's lymphoma
1998 · Lynn R. Kong, Cheng-Fang Huang, et al. · Cancer · 33
PDF
High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma
2003 · Jacob D Bitran, Leonard Klein, et al. · Transplantation and Cellular Therapy · 24
Serum levels of carcinoembryonic antigen and a tumor-extracted carcinoembryonic antigen-related antigen in cancer patients.
1982 · J E Shively, V Spayth, et al. · PubMed · 17
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
2022 · Loretta J. Nastoupil, John Kuruvilla, et al. · eJHaem · 16
PDF
Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL)
2015 · Jeff P. Sharman, Leonard M. Klein, et al. · Blood · 16
Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL; Results of a Phase II Trial
2014 · Jeff P. Sharman, Charles M. Farber, et al. · Blood · 16
Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
2009 · R. Jotte, P. Conkling, et al. · Journal of Clinical Oncology · 16
Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)
2016 · Lihua E. Budde, Ahmad Halwani, et al. · Blood · 14
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
2017 · Alexa Cohen, Tanya M. Spektor, et al. · British Journal of Haematology · 13
A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.
2012 · James R. Berenson, James D. Hilger, et al. · Blood · 12
Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
2013 · Jeff P. Sharman, Leonard Klein, et al. · Blood · 10
Phase I trial of misonidazole (NSC#261037) plus cyclophosphamide in solid tumors.
1985 · E Davila, L Klein, et al. · Journal of Clinical Oncology · 9
Results of the dose-escalation portion of a phase 1/2 study (CHAMPION-1) investigating weekly carfilzomib in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
2014 · James R. Berenson, Leonard M. Klein, et al. · Journal of Clinical Oncology · 8
Phase 2 trial of GS-9973, a selective Syk inhibitor, in chronic lymphocytic leukemia (CLL).
2014 · Jeff Porter Sharman, Leonard M. Klein, et al. · Journal of Clinical Oncology · 8
Works count: 57
Citation count: 1,927
H-index: 16
I10-index: 22
Year
Topic
Type